GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer.
The study will combine molecular imaging, blood-based biomarkers, and clinical data to evaluate whether treatment can be tailored to each patient’s response instead of following a fixed number of therapy cycles.
Using StarGuide™ SPECT/CT technology and MIM LesionID Pro, researchers aim to identify predictive markers that support more precise treatment decisions while improving patient outcomes and expanding access to theranostic care.
“This collaboration is an example of how Mayo Clinic leads in discovery by integrating novel technologies into our practice and accelerating innovation across research and clinical care to advance the future of medicine,” says Andrew Danielsen, chief business development officer at Mayo Clinic. “By bringing together complementary expertise and capabilities, we can enable our world-class researchers and physicians to develop new insights, expand treatment possibilities, and ultimately provide the best outcomes for our patients globally.”
Click here to join our WhatsApp channel here
The research will be conducted at Mayo Clinic’s Rochester, Minnesota campus and builds on the organizations’ ongoing collaboration to advance precision oncology through innovation in medical imaging and data-driven care.
“Personalizing therapy is both a scientific pursuit and an opportunity to expand patient access,” says Geoffrey Johnson, M.D., Ph.D., chair of the Radiopharmaceutical Trial Team at Mayo Clinic Comprehensive Cancer Center. “Theranostics, and studies such as MI-BET, give us an important opportunity to rethink how and when we treat cancer. By evaluating response earlier in their treatment, we can generate data to drive approaches that could help reduce unnecessary therapy while expanding access to care for wider populations.”
